Adriatic Metals achieves key milestone at Vares

|

Published 04-SEP-2018 11:45 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Adriatic Metals (ASX:ADT) has provided an update on its Vares Project in Bosnia.

The Federal Ministry of Mining within the Federation of Bosnia & Herzegovina (FERMI), has provided written acknowledgement of the completion of the Reserves Elaborat for the Veovaca deposit, which is within the broader Vares Project.

ADT drilled 16 confirmation holes at the Veovaca deposit in 2017, which was an operational open pit mine in the past. The company defined a JORC 2012 resource at the site off the back of the drilling, which contained 7.3m tonnes at a 0.5% zinc equivalent cut off.

Under the terms of its Concession Agreement, ADT is required to complete the conditions of the Exploitation Permit by May 2020. If satisfied, the company will be granted with a license tenure at the site until 2038, which may be further extended by ADT for a period of 10 years.

In addition to the Reserve Elaborat, ADT is required to submit the following:

  • Environmental Impact Study
  • In-principle Site Plan and a Mining Plan
  • Land Access Agreements
  • Urban Planning Permit

The company is now expediting these conditions, and expects to receive the Exploitation Permit by Q4 2019.

Of course, as with all minerals exploration, success is not guaranteed — consider your own personal circumstances before investing, and seek professional financial advice.

Because ADT is the principle private land owner at Veovaca, it does not foresee any complications in completing the above requirements.

The Concession Agreement covers Veovaca I & II and Rupice-Jurasavec Brestic, with the granting of the Exploitation Agreement to extend the licence tenure on all Fields to May 2038 by default.

The company concluded its update by touching on its Reserve Elaborat for Rupice-Jurasavec Brestic, which it plans to complete in H1-2019 following its current drilling program.

Upon receiving the Exploitation Permit, ADT will submit a Main Mining Plan (Feasibility Study) and apply for a Water Management Permit. These permits, once approved, will result in an Operations Permit being issued.

ADT CEO Geraint Harris commented on the strong update, “The acceptance of the Reserve Elaborate for Veovaca is a major milestone in the permitting of the Vares Project. Whilst exploration continues at Rupice we are working to align the permitting time-lines for all fields.

“We are privileged to have a strong support of government at all levels in Bosnia, as well as our local community in Vares, as has been demonstrated by the recent approval of the land expansion of the Concession by the Vares Municipality,” he said.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X